Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage (NCT07305896) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage
1,248 participantsStarted 2025-12-31
Plain-language summary
This study plans to enroll 1248 patients with supratentorial ICH within 24 hours of onset across multiple stroke centers. After randomization, the control group will only receive medical therapy. The experimental group, after randomization, will receive an initial dose of 200 mg of minocycline hydrochloride capsules in addition to medical ttherapy, followed by 100 mg orally every 12 hours for 7 days, resulting in a total of 14 administrations. Both groups will be followed for 180 days to evaluate the efficacy and safety of minocycline in the treatment of ICH.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 18 years, regardless of gender;
✓. Supratentorial ICH confirmed by brain CT scan;
✓. No disability in the community before ICH (premorbid mRS≤1);
✓. Neurological deficits related to the hematoma, with NIHSS score ≥ 6 and single-limb motor item score ≥ 2;
✓. GCS score ≥ 6;
✓. Able to initiate the first dose of minocycline within 24 hours of onset;
✓. Signed and dated informed consent.
Exclusion criteria
✕. Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs;
✕. Allergy to tetracycline antibiotics;
✕. Use of vitamin A derivatives or steroid therapy within the past 3 months;
✕. Concomitant infection requiring antibiotic treatment at admission;
✕. Planned surgical intervention;
✕. Life expectancy of less than 6 months due to comorbid conditions;
✕. Severe hepatic and renal dysfunction, or AST and/or ALT \>3 times the upper limit of reference range, or serum creatinine \>265 μmol/L (\> 3 mg/dL);
What they're measuring
1
The proportion of patients with favorable functional outcomes, defined as mRS 0-2 at 180 days.
✕. Bleeding tendency, including heparin use within the past 48 hours (APTT ≥ 35 s), oral warfarin (INR \> 2), platelet count \< 100 × 10⁹/L, or hereditary hemorrhagic diseases;